(S)-2-氨基-2-苯乙酸叔丁酯 | 53934-78-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-氨基-2-苯乙酸叔丁酯
• 英文名称: L-Phg-O^tBu
• 英文别名: H-L-Phg-O^tBu；(S)-tert-Butyl 2-amino-2-phenylacetate；tert-butyl (2S)-2-amino-2-phenylacetate
• CAS: 53934-78-4
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD00238136
• 分子量: 207.272
• InChiKey: HJLYKRGXTOVWFL-JTQLQIEISA-N

物化性质

• 沸点：
  280.2±20.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  密封存储，在-15°C下保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Phg-otbu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Phg-otbu
CAS number: 53934-78-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17NO2
Molecular weight: 207.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-2-氨基-2-苯乙酸叔丁酯 在 盐酸 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 27.5h， 生成 N-甲氧羰基-L-苯基甘氨酸
  参考文献：
  名称：

  丙肝聚合酶抑制剂

  摘要：

  本发明涉及一种4，4’‑双(2‑((S)‑吡咯烷‑2‑基)‑1H‑咪唑‑4‑基)联苯类化合物及其衍生物，本发明所述化合物为HCV聚合酶抑制剂，具有抗HCV的活性，可用于治疗HCV感染患者。

  公开号：

  CN103304551B
• 作为产物：
  描述：

  Fms-Phg-OtBu 在 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 (S)-2-氨基-2-苯乙酸叔丁酯
  参考文献：
  名称：

  (9H-Fluoren-9-yl)methanesulfonyl (Fms)：与 Fmoc 互补的氨基保护基团

  摘要：

  开发了基于磺酰胺的保护基团 (PG)，(9H-芴-9-基) 甲磺酰基 (Fms)，其使用方式与成熟的 Fmoc PG 类似。这种新型 PG 的优势在 N-Fms 保护的 α-膦酰基丙氨酸单酯和仲烷基胺（包括 (R)-2-苯乙胺、(S)-苯丙氨酸叔丁酯 (H) -Phe-OtBu)、H-Pro-Gly-OtBu 和 H-Phe-Phe-OtBu，不会形成氧氮杂膦，这是与 Fmoc PG 相关的严重问题。这一成功应该为在基本上任意位置用 α-氨基膦酸 (AP) 取代的非天然肽的固相合成铺平道路，而无需对自 Carpino 在 1970 年的报告以来积累的基于 Fmoc 的化学进行重大修改。

  DOI：

  10.1002/ejoc.201000682

文献信息

• Allenone-Mediated Racemization/Epimerization-Free Peptide Bond Formation and Its Application in Peptide Synthesis
  作者：Zhengning Wang、Xuewei Wang、Penghui Wang、Junfeng Zhao

  DOI：10.1021/jacs.1c04614

  日期：2021.7.14

  peptide synthesis (SPPS). The robustness of the allenone-mediated peptide bond formation was showcased incisively by the synthesis of carfilzomib, which involved a rare racemization-/epimerization-free N to C peptide elongation strategy. Furthermore, the successful synthesis of the model difficult peptide ACP (65–74) on a solid support suggested that this method was compatible with SPPS. This method combines

  Allenone 首次被鉴定为一种高效的肽偶联剂。肽键以α-羰基乙烯基酯为关键中间体形成，其形成和随后的氨解以无外消旋/差向异构化的方式自发进行。丙二烯酮偶联试剂不仅对简单酰胺和二肽的合成有效，而且还适用于肽片段缩合和固相肽合成 (SPPS)。卡非佐米的合成充分展示了丙二烯酮介导的肽键形成的稳健性，该合成涉及一种罕见的无消旋化/差向异构化的 N 到 C 肽延伸策略。此外，在固体支持物上成功合成模型困难肽 ACP (65-74) 表明该方法与 SPPS 兼容。该方法结合了传统活性酯和偶联剂的优点，同时克服了两种策略的缺点。因此，这种丙二烯酮介导的肽键形成策略代表了肽合成的颠覆性创新。
• Hepatitis C Virus Inhibitors
  申请人：Belema Makonen

  公开号：US20100080772A1

  公开（公告）日：2010-04-01

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• Substrate-Directed Lewis-Acid Catalysis for Peptide Synthesis
  作者：Wataru Muramatsu、Tomohiro Hattori、Hisashi Yamamoto

  DOI：10.1021/jacs.9b03850

  日期：2019.8.7

  A Lewis-acid-catalyzed method for the substrate-directed formation of peptide bonds has been developed, and this powerful approach is utilized for the new "remote" activation of carboxyl groups under solvent-free conditions. The presented method has the following advantages: 1) the high-yielding peptide synthesis uses a tantalum catalyst for any amino acids; 2) the reaction proceeds without any racemization;

  一种路易斯酸催化的底物定向形成肽键的方法已经被开发出来，这种强大的方法被用于在无溶剂条件下对羧基进行新的“远程”活化。该方法具有以下优点：1）高产肽合成对任何氨基酸均使用钽催化剂；2) 反应进行时没有任何外消旋化；3）采用钛催化剂的新型底物导向化学连接适用于会聚肽合成。这些优势克服了经典肽合成中一些未解决的问题。
• TETRACYCLIC CDK9 KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：US20150218165A1

  公开（公告）日：2015-08-06

  Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R 1 , R 2 , R 3A , R 3B , and R 4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

  公开了公式(Ia)的化合物，以及其中X、Y、R1、R2、R3A、R3B和R4如本文所述的药用可接受盐。这些化合物可用作治疗疾病(包括癌症)的药物。还公开了包含一个或多个公式(Ia)化合物的药物组合物。
• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。